Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biomarkers 2014

Alan Palmer's Biography



Alan Palmer, CSO, MS Therapeutics

Alan has formed or co-founded six biotech start-up companies. He is presently a Board director of Cerebroscience, MS Therapeutics Ltd, One Nucleus, Neuro 360 and the British Neuroscience Association. With over 100 peer-reviewed papers to his name, his scientific research has had a high impact, particularly in the study of dementia and traumatic brain injury. Alan is visiting Professor at University College London and the University of Reading and Life Science Entrepreneur in Residence at the University of Bristol. He was voted London Biotechnology Network Entrepreneur of the Year in 2005.

Alan Palmer Image

The Utility of Biomarkers in CNS Drug Development

Wednesday, 9 July 2014 at 11:00

Add to Calendar ▼2014-07-09 11:00:002014-07-09 12:00:00Europe/LondonThe Utility of Biomarkers in CNS Drug DevelopmentBiomarkers 2014 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

The utility of biomarkers (especially neuroimaging biomarkers) in the development of CNS drug candidates will be described with respect to: improving patient homogeneity, establishing target engagement, providing a pharmacodynamic read-out and providing a measure of disease progression.


Add to Calendar ▼2014-07-08 00:00:002014-07-09 00:00:00Europe/LondonBiomarkers 2014Biomarkers 2014 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com